Pharma Focus Asia

Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”

Thursday, July 07, 2022

Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that the two companies signed a sales collaboration agreement in Japan for Tirzepatide, which is under development by Eli Lilly Japan.

Tirzepatide (injection) is a novel once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of the GIP and GLP-1 in-cretins into a single molecule, representing a new class of medicines being developed for the treatment of type 2 diabetes by Eli Lilly Japan. In the U.S., Tirzepatide was already FDA-approved on May 13 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Based on the agreement, after Eli Lilly Japan retains a manufacturing/marketing license for Tirzepatide, MTPC will take responsibility for sales/distribution of the medicine. Eli Lilly Japan and MTPC will conduct activities to provide healthcare professionals with information regarding Tirzepatide.

Eli Lilly Japan continues to provide a broad product portfolio and unique services to meet the various needs of people living with diabetes. MTPC has developed several antidiabetic drugs and is engaged in information provision activities in the diabetes field in order to creating hope to all facing illness. The two companies entered into this alliance because we believe that by working together, we can provide appropriate information to a wide range of medical institutions and deliver Tirzepatide promptly to a greater number of patients who need it.

Eli Lilly Japan and MTPC will closely work together through the sales collaboration for Tirzepatide, which is expected to be a new option for the treatment of type 2 diabetes, and make further contributions to the treatment of diabetes.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024